New Chemicals Could Lead To First Bone Growth Pill

March 22, 1999

ANAHEIM, Calif., March 21 -- New chemicals that, if successful, could become the first osteoporosis treatment to stimulate new bone growth -- rather than merely retard bone loss -- were described here today at a national meeting of the American Chemical Society, the world's largest scientific society. Researchers from the Seattle biotechnology company ZymoGenetics Incorporated said their new compounds are showing positive results in animals and, unlike other bone-growth candidates, can be put in a pill.

In humans, bone undergoes continuous remodeling, with cells called osteoclasts "eating up"old bone as osteoblast cells replace it with new bone. Osteoporosis, which affects some 15-20 million Americans, is caused by increased bone breakdown without new bone formation. The result is a loss of bone mass and increased susceptibility to fractures, most commonly in those age 45 and older. The cost of treatments associated with osteoporosis in the U.S. has been estimated at $3.8 billion annually.

Current treatments, including estrogens, all act to decrease bone loss. They can't do anything about bone that is already gone and, therefore, are not helpful to everyone. "Our new bone forming agents may have better and more widespread utility for treatment of osteoporosis," said ZymoGenetics senior scientist Nand Baindur, Ph.D.

There are currently no drugs available to help grow bone. Researchers have tried giving patients proteins that the body naturally uses to stimulate osteoblasts, such as parathyroid hormone and bone morphogenic proteins (BMPs). But, according to Dr. Baindur, those clinical trials have been mostly unsuccessful or inconclusive. Furthermore, he explains that proteins are big molecules which can usually be given only by injection and don't hold up well in the body. Even if such treatments worked, he adds, the proteins are generally difficult to formulate and manufacture, tending to eventually make them expensive.

Instead of using the proteins themselves, Dr. Baindur's laboratory screened tens of thousands of compounds for the ability to stimulate BMPs. They have selected three -- two synthetic chemicals and one natural product -- for pre-clinical development, and early indications look promising. "This is the first report of small molecule drug-like compounds which have been shown to stimulate the formation of new bone in animals," says Dr. Baindur.

Such small molecule compounds are not only relatively inexpensive and easily made, but usually quite stable. Dr. Baindur adds that they can also be easily modified or formulated as the need arises. The new compounds should be able to be put into pill form. While no human tests have yet been conducted, Dr. Baindur says "these compounds are predicted to be useful in the clinical treatment of osteoporosis and related bone-deficit conditions, including bone fractures. As bone formation agents, they can potentially be given alone or in combination with agents which decrease bone loss."

While bone regenerating pills are probably years away from the market, there is the possibility that one of the new compounds might have a head start in clinical trials. The natural product candidate is part of a chemical class called statins, some of which are already in use for the treatment of heart disease.
Dr. Baindur will present this poster, MEDI 76, on Sunday, March 21, at 7:30 p.m., at the Convention Center A1.

A nonprofit organization with a membership of nearly 159,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.

American Chemical Society

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to